Contraception
632
35
52
463
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
168 trials with published results (27%)
Research Maturity
463 completed trials (73% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.1%
32 terminated out of 632 trials
93.5%
+7.0% vs benchmark
28%
177 trials in Phase 3/4
36%
168 of 463 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 463 completed trials
Clinical Trials (632)
Verbal Analgesia During Copper IUD Insertion After Cesarean Delivery
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
Postpartum Integration of Vaccines and Contraception Trial
Female Reproductive Health in Canadian Armed Forces
Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
DYnamic decisioN Support for IntegrAting PrEP in Clinics for Young People in Alabama and Botswana
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Long Term Evaluation of Scapular-inserted Contraceptive Implants
Contraceptive Efficacy Study of Ovaprene
Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIV
Validation of Effectiveness on NaturalCycles Users
"Vasectomy: Right for Me?" Decision Support Tool
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women
Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive Pill
Evaluation of the Efficacy and Safety of LevoCept
European Active Surveillance Study of LCS12
A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles
Hormonal Influences on Inflammatory Bowel Diseases